Cordatus Wealth Management’s AbbVie ABBV Stock Holding History

Cordatus Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.56M	Sell	16,380 -225	-1%	-$49.9K	0.85%	35
2025 Q4	$3.79M	Buy	16,605 +3	+0%	+$683	0.88%	28
2025 Q3	$3.84M	Buy	16,602 +102	+0.6%	+$20.8K	0.91%	28
2025 Q2	$3.06M	Sell	16,500 -7	-0%	-$1.3K	0.75%	35
2025 Q1	$3.46M	Buy	16,507 +527	+3%	+$102K	0.95%	28
2024 Q4	$2.84M	Buy	15,980 +642	+4%	+$118K	0.75%	41
2024 Q3	$3.03M	Buy	15,338 +146	+1%	+$27.2K	1.09%	25
2024 Q2	$2.61M	Buy	15,192 +2,100	+16%	+$348K	0.98%	28
2024 Q1	$2.38M	Buy	13,092 +70	+0.5%	+$12.1K	1.73%	18
2023 Q4	$2.02M	Sell	13,022 -1,626	-11%	-$237K	1.67%	18
2023 Q3	$2.18M	Sell	14,648 -153	-1%	-$22.5K	1.99%	16
2023 Q2	$1.99M	Buy	14,801 +12,938	+694%	+$1.9M	0.75%	45
2023 Q1	$297K	Hold	1,863	–	–	0.38%	52
2022 Q4	$301K	Buy	+1,863	New	+$286K	0.44%	48

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cordatus Wealth Management's ABBV Position: Q1 2026 in Review

Cordatus Wealth Management reduced its AbbVie (ABBV) stake by 1.4% in Q1 2026, selling an estimated $49.9K and leaving 16,380 shares worth $3.56M. The position accounts for 0.85% of the portfolio, ranked #35.

Cordatus Wealth Management first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.84M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Cordatus Wealth Management held 16,380 shares of AbbVie worth $3.56M as of Q1 2026.
Cordatus Wealth Management sold 225 AbbVie shares in Q1 2026, an estimated $49.9K.
AbbVie made up 0.85% of Cordatus Wealth Management's portfolio in Q1 2026, its #35 holding.
Cordatus Wealth Management first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Cordatus Wealth Management's AbbVie position peaked at $3.84M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cordatus Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.